Thyroid Cancer

The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer.

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population.

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer.

From a Netflix star revealing a breast cancer diagnosis to “Good Morning America” host Robin Roberts sharing what emotions she felt when partner Amber Laign was diagnosed with breast cancer, here’s what is happening in the cancer space this week.

Considerations for the role of patient advocacy groups and patient-to-patient education in the differentiated thyroid cancer journey.

Monumental treatment advancements over the past two decades have given patients with thyroid cancer the ability to live longer and better lives, according to an expert from Cleveland Clinic’s Taussig Cancer Institute. However, more work is needed to find curative treatments.

Expert perspectives on the broad management of differentiated thyroid cancer, including surgery, radiation treatment, and systemic therapy.

Health care specialists provide an overview on the nature of differentiated thyroid cancer and discuss subtypes of disease that patients may present with.

Although certain cancer treatments have been linked to an increased risk of a secondary cancer years later, an expert notes there are no genetic or pathologic studies that prove the association between new and previous cancers.

Guidelines for the treatment of patients with brain metastases is moving from whole brain radiation therapy to less toxic treatment options to potentially improve care and increase survival.

After four years of additional follow-up, survival continued to improve and side effects remained tolerable in patients with anaplastic thyroid cancer receiving Tafinlar plus Mekinist.

From the death of a former New York Mets player due to cancer, to a lawsuit against Tokyo Electric Power Company Holdings regarding cancer potentially caused by the 2011 Fukushima nuclear disaster, here’s what’s happening in the cancer landscape this week.

The tome also reflects on his own diagnosis of cancer and how it influenced his practice.

The FDA approval of Cabometyx was based on results that showed that the drug was associated with improved outcomes in patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer.

Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

New research sheds lights on the causes of thyroid cancer, overdiagnosis of PTC

Data from a recent study found that while the risk of developing cancer is 1.74 times greater for individuals born with major birth defects, that risk is highest in childhood but decreases slightly after age 20.

The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.